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The use of positron imaging agents such as FDG, MET, and FLT is expected to lead the way for novel applications toward eﬃcient
malignancy grading and treatment of gliomas. In this study, the usefulness of FDG, MET and FLT-PET images was retrospectively
reviewed bycomparing their histopathological ﬁndings.FDG, MET,and FLT-PETwere performedin27patients withWHO grade
IV,15patientswithWHOgradeIII,and12patientswithWHOgradeIIduring5.5years.TheresultingPETimageswerecompared
by measuring SUVs and T/N ratios (tumor to normal tissue ratios). Although there were no signiﬁcant diﬀerences in FDG-PET,
there were signiﬁcant diﬀerences in the T/N ratios in the MET-PET between WHO grades II and IV and in the FLT-PET between
the WHO grades III and IV. In glioblastoma patients, the SUVs of the areas depicted by MRI in the MET-PET were diﬀerent from
those SUVs in the FLT-PET. Importantly, the areas with high SUVs in both MET-PET and FLT-PET were also high in Ki-67 index
and were histologically highly malignant. PET imaging is a noninvasive modality that is useful in determining a tumor area for
removal as well as improving preoperative diagnosis for gliomas.
1.Introduction
Morphological imaging using magnetic resonance imaging
(MRI) is the most commonly used method for obtain-
ing tumor information. Gd-enhanced T1-weighted MRI
provides anatomical imaging with hyperintense neovas-
cularization enclosed in a hypointense region of central
necrosis.Inaddition,ﬂuid-attenuatedIR(FLAIR)detectsthe
surrounding edema associated with inﬁltrating tumor cells
[1]. The use of positron emission tomography (PET), an
imaging modality providing metabolic and molecular infor-
mation, can improve diagnostic procedures in malignant
brain tumors. 2-Deoxy-2-[18F] ﬂuoro-D-glucose (FDG), a
commonly used tracer for neoplasm detection, exhibits
limited utility in brain tumor imaging, because the uptake
is nonspeciﬁc and can occur in any region with increased
metabolicactivity. Moreover,nonspeciﬁcFDGuptakecanbe
increased by some inﬂammatory diseases. In addition, FDG-
PET is a marker of glycolytic metabolism and not cellular
proliferation. The information it provides is therefore com-
plementary to other imaging techniques [2–5].
L-Methyl-11C-methionine (MET) is a well-established
PET radiotracer for brain tumor detection and tumor
delineation [6, 7]. Amino acids, including MET, readily cross
the intact blood-brain barrier (BBB) through neutral amino
acid transporters and are incorporated into the area with
active tumor [8]. It has been shown that MET uptake in
gliomas signiﬁcantly correlates with the WHO tumor grade
and cell proliferation determined by Ki-67 index [4, 9–11].
However, increased MET uptake in nonneoplastic lesions
including inﬂammation, infarction, and hemorrhage may
result in false positives [12, 13]. Also, the short half-life of
11C (20min) and rapid in vivo degradation make MET-PET
less useful for routine clinical use.
A ﬂuorinated thymidine analog, 3 -deoxy-3 -[18F] ﬂu-
orothymidine (FLT), has emerged as a promising PET
tracer for evaluating tumor-proliferating activity in various
malignant brain tumors [3, 14, 15]. FLT is phosphorylated2 Journal of Biomedicine and Biotechnology
by thymidine kinase-1 (TK1), a principle enzyme in the
salvage pathway of DNA synthesis, and trapped inside the
cells. Phosphorylated FLT appears resistant to degradation
and is suitable for imaging with PET. The application of
FLT phosphorylation as a marker of cell proliferation is
based on the assumption that cellular FLT trapping is a
representation of thymidine incorporation into DNA [16,
17]. Since FLT uptake in the normal brain tissue is very low,
FLT-PET provides a low-background brain image, making
it an ideal PET tracer for the imaging of brain tumors.
FLT-PET has been found useful for noninvasive grading of
gliomas [18]. In addition, FLT-PET has been utilized in the
prognostic assessment and evaluation of treatment response
in malignant gliomas [19].
Despite the superior features MET and FLT oﬀer as
glioma cell tracers, they are also associated with several
problems. The cut-oﬀ value of normal versus tumor cell
inﬁltration is diﬃcult to determine. Therefore, the purpose
of this prospective study was to clarify the individual and
combined roles of FDG-PET, MET-PET, and FLT-PET in
tumordetection,noninvasivegrading,andassessmentofcel-
lular proliferation rate in 54 newly diagnosed histologically
veriﬁed gliomas of diﬀerent grades.
2.MaterialsandMethods
2.1. Patients. From April 2006 through October 2011, 54
patients with newly diagnosed gliomas (23 men and 31
women; mean age: 52.0 ± 18.1y; range: 22–86y) were
enrolled in this study (Table 1). The use of FDG, MET, and
FLT as a PET tracer was approved by the Kagawa University
School of Medicine Human Subjects Ethics Committee, and
informedwrittenconsentwasobtainedfromallpatientswho
participated in this study. Histopathology was performed
on tissue specimens obtained by biopsy or resection. All
tumors were graded by the World Health Organization
(WHO) grading system (malignancy scale) for CNS tumors.
Tumor types and grades were distributed as follows and
listed in Table 1:W H Og r a d eI Id i ﬀuse astrocytoma (n =
9), WHO grade II oligoastrocytoma (n = 2), WHO grade
II oligodendroglioma (n = 1), WHO grade III anaplastic
astrocytoma (n = 11), anaplastic oligoastrocytoma (n = 3),
WHOgradeIIIanaplasticoligodendroglioma(n = 1),WHO
grade IV glioblastoma multiforme (n = 26), WHO grade IV
gliosarcoma (n = 1).
2.2. Proliferation Analysis. Surgical specimens were ﬁxed
in 10% formalin and embedded in paraﬃn. Hematoxylin-
and-eosin-stained specimens were checked to determine the
histological tumor type. The cellular proliferation activity
of the tumor was determined by measuring the Ki-67
proliferation index obtained by immunohistochemical stain-
ing with anti-Ki-67/MIB-1 antibody (Dako, Tokyo, Japan).
Immunohistochemical slides were examined at high-power
magniﬁcation (×400). The percentage of tumor cells which
stained positively for Ki-67 antigen was measured in the area
containingthelargestnumberofpositivetumorcellsandwas
regarded as representative of the tumor proliferation activity.
2.3. PET Examination. PET studies were performed using
an ECAT EXACT HR + scanner and a Biograph mCT 64
(Siemens/CTI, Knoxville, TN, USA) in three-dimensional
acquisition mode. The image system enabled the simulta-
neous acquisition of 51 transverses per ﬁeld of view (FOV),
with intersection spacing of 3mm, for a total axial FOV of
15cm. The in-plane (transverse) reconstructed resolution
was 4.7mm full-width at half-maximum (FWHM) in the
brain FOV. Images were reconstructed using the ﬁltered
backprojectionmethodwithaHanningﬁlter(kernelFWHM
10mm, cutoﬀ frequency 0.4 cycle/projection element) to
generate 128 × 128 matrices.
PET radiotracers were produced using the HM-18 cyclo-
tron (Sumitomo Heavy Industries, Tokyo, Japan). FLT was
synthesizedusingthemethoddescribedbyShieldsetal.[16],
andtheradiochemicalpurityoftheproducedFLTwas>95%.
MET was produced by proton bombardment of 14N2.T h e
resultant 11CO2 was reduced to 11C-methanol by lithium
aluminum hydride and subsequently converted to 11C-CH3I
by the addition of hydrogen iodide following the modiﬁed
method described by Ishiwata et al. [20]. The radiochemical
purity of the produced MET was >95%.
Each patient received the FDG, MET, and FLT one by
one for a continuous 3-day course before the surgery. For
the FDG-PET study, enteral and parental sources of glucose
were withheld for at least 6h before the examination. No
special dietary instructions were given to the patients before
the MET and FLT-PET examination. Images were acquired
with patients in the supine position, resting, with their eyes
closed. Using 68Ge rod sources rotating around the head,
transmission images of the brain were obtained for 5min
for FDG-PET, 3min for MET-PET, and 5min for FLT-PET.
Transmission scan with 68Ge rod can be replaced to CT
attenuation correction in mCT64 system. A dose of 147–
295MBq (mean dose: 208 ± 39MBq) of 18F-FDG, 113–
389MBq (mean dose: 211 ± 65 MBq) of 11C-MET, or 129–
236MBq(meandose: 161±25MBq) of 18F-FLTwasinjected
intravenously. Regional emission images of the brain were
obtained for 5min, beginning 45min after the 18F-FDG
injection; for 5min, beginning 10min after the 11C-MET
injection; for 10min, beginning 40min after the 18F-FLT
injection.
2.4. Image Analysis. FDG, MET, and FLT uptake in the brain
tumor were semiquantitatively assessed by evaluating the
standardized uptake value (SUV). A region of interest (ROI)
was set manually by an observer around the hottest area
of each lesion. The maximum value of SUV (SUV max)
was regarded as the representative value of each tumor. To
calculate the tumor-to-normal tissue count density (T/N)
ratios, the ROI was set on the normal brain parenchyma
(usually contralateral normal cerebral tissue excluding ven-
tricles) and the mean value of SUV (SUV mean) was
calculated. The T/N ratio was determined by dividing the
SUV max of the tumor by the SUV mean of the normal
brain tissue. The PET and MRI datasets were transferred to
a LINUX workstation. Co-registration of FDG-PET/MET-
PET/FLT-PET/MRI was undertaken on the workstation with
a commercial software package (Dr. View/LINUX, versionJournal of Biomedicine and Biotechnology 3
Table 1: Patient characteristics and semiquantitative PET results for FDG, MET, and FLT. Dig: histological diagnosis, DA: diﬀuse
astrocytoma, OA: oligoastrocytoma, O: oligodendroglioma, AA: anaplastic astrocytoma, AOA: anaplastic oligoastrocytoma, AO: anaplastic
oligodendroglioma, GBM: glioblastoma multiforme, GS: gliosarcoma, SUV max maximum standardized uptake value, T/N ratio tumor-to-
normal tissue count density.
Case Age Sex Dig. Ki-67 (%) FDG
SUV max FDG T/N MET
SUV max MET T/N FLT SUV
max FLT T/N
1 49 f DA 1.75 4.12 0.403526 2.93 1.7757576 0.13 1.1818182
2 42 f OA 7.5 4.4 0.5231867 4.37 2.5406977 0.24 1.8461538
3 52 f DA 1 4.96 0.5025329 3.34 1.9306358 0.55 3.6666667
4 71 m DA 4 3.85 0.6514382 5.28 4.3278689 0.76 5.4285714
5 30 m DA 2.5 5.65 0.495614 1.69 1 0.28 1
6 35 f DA 2.5 5.78 0.5254545 1.57 1 0.23 1
7 30 f DA 5 5.89 0.356 1.49 1.18254 0.18 1
8 27 f O 2.3 5.34 0.8215385 1.38 1.5164835 0.18 1.125
9 49 f DA 5 2.71 0.5441767 1.7 1.1971831 0.22 1.047619
10 38 f DA 5 6.07 0.497133 2.55 1.795775 0.28 1.75
11 37 m DA 1 23.87 2.69 4.97 2.99 0.79 2.72
12 36 m OA 7.7 8.01 1.055336 5.26 3.094118 0.48 2.181818
13 34 f AA 5 6.67 0.6778455 3.22 2.2517483 1.15 6.7647059
14 58 m AA 12.5 4.46 0.566709 3.55 2.9583333 0.28 1.8666667
15 77 f AA 35 6.98 1.8082902 5.07 3.5454545 0.9 5
16 26 m AA 5 4.72 0.5777234 3.32 2.862069 0.32 2.6666667
17 66 f AOA 5 3.97 0.5321716 2.93 2.4016393 0.58 3.0526316
18 60 f AA 10 7.59 1.1587786 3.41 2.544776 0.94 3.91667
19 36 f AA 6 4.27 0.5488432 4.81 2.829412 0.37 2.176471
20 43 f AA 30 4.74 0.629482 8.04 4.345946 0.84 2.470588
21 71 m AOA 50 24.02 3.1605263 5.17 4.3445378 1.45 6.3043478
22 64 m AO 50 8.74 1.208852 8.18 6.544 2.51 9.653846
23 28 f AOA 5 13.5 1.674938 9.02 5.401198 0.98 2.227273
24 79 f AA 5 47.57 5.3032329 5.96 3.8701299 0.77 5.1333333
25 66 f AA 12.5 6.23 0.7634803 2.61 1.482955 0.66 2.357143
26 31 f AA 20 23.05 2.845679 6.49 4.570423 1.64 9.647059
27 45 m AA 7.5 14.8 1.9865772 6.61 5.1640625 1.06 3.2121212
28 51 m GBM 25 14.86 2.006192 20.88 5.7246377 11.18 6.0812183
29 22 f GBM 40 12.69 1.4859485 5.21 3.196319 3.05 11.296296
30 62 m GBM 35 7.65 0.9634761 4.55 3.64 1.19 7
31 70 f GBM 35 5.04 0.6990291 3.44 2.3401361 1.37 6.2272727
32 81 f GBM 50 13.05 2.8935698 5.69 3.6012658 3.74 15.583333
33 55 f GBM 35 8.99 2.5759312 5.35 3.4294872 2.61 3.1829268
34 29 f GBM 50 5.5 0.607064 3.57 1.9944134 1.66 8.7368421
35 77 f GBM 45 4.6 1.281337 5.51 3.3393939 2.15 8.9583333
36 79 m GBM 65 9.71 2.0442105 4.3 3.5833333 3.68 17.52381
37 69 f GBM 15 15.1 2.2913505 4.98 3.254902 4.41 23.210526
38 86 f GBM 30 10.96 1.7734627 5.91 5.472222 2.69 15.82353
39 27 f GBM 30 6.51 1.4563758 3.83 2.992188 1.53 6.652174
40 61 m GBM 10 6.07 1.0049669 3.68 3.2857143 1.96 7.5384615
41 53 m GBM 25 6.61 1.0200617 3.31 3.412371 1.7 8.5
42 62 m GBM 70 4.86 0.9382239 4.54 4.09009 1.67 15.18182
43 67 m GBM 30 5.8 0.9148265 2.82 2.014286 1.45 9.0625
44 60 m GBM 40 5.97 0.894615 2.9 2.788462 1.28 7.111111
45 54 m GS 40 6.95 0.8742138 3.75 2.218935 2.9 12.60874 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Case Age Sex Dig. Ki-67 (%) FDG
SUV max FDG T/N MET
SUV max MET T/N FLT SUV
max FLT T/N
46 72 m GBM 50 5.55 0.9771127 3.22 2.439394 2.28 16.28571
47 68 f GBM 60 5.94 1.1020408 4.08 2.4 2.99 17.58824
48 53 f GBM 20 4.76 0.6979472 2.63 1.992424 1.04 6.1176471
49 61 f GBM 70 12.2 1.75 5.64 5.271028 1.58 5.8518519
50 37 m GBM 20 10.31 1.19 14.08 9.7777778 1.73 6.1785714
51 33 m GBM 70 20.16 2.011976 8.71 4.608466 2.85 8.6363636
52 41 f GBM 20 24.76 3.4057771 7.04 5.1764706 2.22 17.076923
53 26 m GBM 80 13.32 1.5857143 5.43 3.878571 2.59 4.177419
54 69 m GBM 90 27.09 5.0166667 8.86 7.5726496 5.44 34
R2.5, AJS Inc., Tokyo, Japan) with the mutual information
method. The software allowed an operator to perform
manual intervention; however, required adjustment for co-
registration was minimal.
The measured SUV max and T/Nr a t i o so fF D G ,M E T
and FLT were compared with the histological diagnoses
obtained by biopsy or resection. The relationships between
the Ki-67 index and SUV max or T/N ratio of FDG, MET
and FLT were evaluated. The relationship between FDG and
MET or FLT and MET uptake were evaluated. Regarding the
area with a high-intensity signal on the MRI (FLAIR) of each
patient, based on a predetermined ROI, the mean SUVs of
FDG,METandFLTwereusedtocomparethevaluesbetween
F D Ga n dM E T ,b e t w e e nF L Ta n dM E T ,a n db e t w e e nF D G
and FLT.
2.5. Statistical Analysis. All parametric data were expressed
as mean ± standard deviation. The Mann-Whitney U test
wasusedtoassessthestatisticalsigniﬁcanceinmeanvolumes
across modalities. The Spearman correlation test was used
to calculatethe correlation coeﬃcient. Statistical analysiswas
performed using Stat View J-5.0 for Windows.
3. Results
3.1. Patient Characteristics and Semiquantitative PET Results
f o rF D G ,M E T ,a n dF L T .Among the 54 glioma cases, the
MET accumulation was observed in 51 cases (94.4%) in the
MET-PET study and the FLT accumulation was observed in
50 cases (92.6%) in the FLT-PET study. Regarding the 3 cases
without the MET accumulation and the 4 cases without the
FLT accumulation, they were grade II gliomas. All malignant
gliomas (grades III and IV) showed accumulation in both
studies. Among the cases with T/N ratios higher than 1 in
the FDG-PET study, there were 2 cases (16.7%) of the grade
II gliomas, 8 cases (53.3%) of the grade III gliomas, and 17
cases (63.0%) of the grade IV gliomas (Table 1). In FDG-
PET study, it is possible to diﬀerentiate gliomas by the WHO
grade with the sensitivity of 53.3%, the speciﬁcity of 55.6%,
the false positive of 44.4%, and the false negative of 46.7%.
I nM E T - P E Ts t u d y ,i ti sp o s s i b l et od i ﬀerentiate gliomas by
WHO grade with the sensitivity of 95.3%, the speciﬁcity
of 9.1%, the false positive of 90.9%, and the false negative
of 4.7%. In MET-PET study, it is possible to diﬀerentiate
gliomas by WHO grade with the sensitivity of 93.9%, the
speciﬁcity of 20%, the false positive of 80%, and the false
negative of 6.1%.
3.2. Comparison of SUV max and T/N Ratios for FDG,
MET, and FLT in Gliomas by WHO Grade. There were no
signiﬁcant diﬀerences in the SUV and T/N ratio among each
group of the diﬀerent WHO grades in the FDG-PET study
(Figures 1(a) and 1(d)).
SUV of the normal brain in the MET-PET study was
1.52 ± 0.36 (0.92–2.62). Regarding the tumors in the MET-
PET study, mean SUV max was 3.04 ± 1.56 for the grade II
gliomas, 5.22 ± 2.09 for the grade III gliomas and 5.12 ±
2.44 for the grade IV gliomas (Figure 1(b)). T/Nr a t i ow a s
2.03 ± 1.02 for the grade II gliomas, 3.67 ± 1.38 for the
grade III gliomas and 3.76 ± 1.78 for the grade IV gliomas
(Figure 1(e)).ThemeanSUVmaxandT/Nratioofthegrade
IV gliomas were signiﬁcantly higher than that of the grade II
gliomas, while there were no signiﬁcant diﬀerences between
the grade II gliomas and grade III gliomas. In the present
study, there were some oligodendroglioma cases, which were
in grade II, but their SUV max were high and ranged from
4 . 0t o6 . 8 .
SUV of the normal brain in the FLT-PET study was
0.20 ± 0.05 (0.13–0.28). Regarding the tumors in the FLT-
PET study, mean SUV max was 0.36 ± 0.23 for the grade II
gliomas, 0.96±0.58 for the grade III gliomas, and 2.38±1.07
for the grade IV gliomas (Figure 1(c)). The mean T/Nr a t i o
was 1.99 ± 1.37 for the grade II gliomas, 4.43 ± 2.61 for the
grade III gliomas and 11.54 ± 6.86 for the grade IV gliomas
(Figure 1(f)). There were signiﬁcant diﬀerences in both SUV
max and T/N ratio between the grade III gliomas and the
grade IV gliomas, but, similar to the MET study, there were
no signiﬁcant diﬀerences between the grade II gliomas and
the grade III gliomas.
3.3. The Correlations between SUV max or T/N Ratio from
PET Studies and Ki-67 Index. When the accumulation of
MET or FLT within the tumor and the Ki-67 index (an index
for proliferation ability of tumor) were compared, linear
regression analysis revealed a signiﬁcant correlation between
the Ki-67 index and MET SUV max (r = 0.32, P = 0.02)Journal of Biomedicine and Biotechnology 5
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Figure 1: Comparison of SUV max and T/N ratios for FDG (a), (d) MET (b), (e) and FLT (c), (f) in gliomas by WHO grade. There were
no signiﬁcant diﬀerences in FDG-PET scan. The diﬀerences in MET SUV max and T/N ratio were statistically signiﬁcant between grades
II and IV gliomas (∗P<0.05), but not signiﬁcant between grade II and III gliomas. The diﬀerences in FLT SUV max and T/Nr a t i ow e r e
statistically signiﬁcant between grade III and IV gliomas, grade II and grade IV ones (∗∗P<0.01).
(Figure 2(b))o rM E TT /Nr a t i o( r = 0.39, P<0.01)
(Figure 2(e)), as well as FLT SUV max (r = 0.73, P<0.001)
(Figure 2(c))o rF L TT /Nr a t i o( r = 0.63, P<0.001)
(Figure 2(f)). FLT, compared to MET, demonstrates a sig-
niﬁcantly strong correlation with the proliferation ability.
In FDG-PET study, linear regression analysis revealed no
correlation between the Ki-67 index and SUV max (r = 0.16,
P = 0.24) (Figure 2(a))o rT /Nr a t i o( r = 0.33, P = 0.02)
(Figure 2(d)).
3.4. Linear Regression Analysis of T/NR a t i ob e t w e e nF D G
and MET and between FLT and MET in Gliomas by WHO
Grade. Regarding the area with a high intensity signal on
the MRI (FLAIR) of each patient, based on a predetermined
ROI, T/N ratio of FDG, MET and FLT were used to
compare the values between FDG and MET, between FLT
and MET and between FDG and FLT. Between FDG and
MET, the T/N ratio of the MET tended to be high without
correlating with increased T/N ratio of the FDG because the
oligodendroglioma components were included in the grade
II or grade III gliomas (Figures 3(a) and 3(b)). T/Nr a t i oo f
the FDG tended to be high with correlating with low T/N
ratio of the MET showing a tendency toward the focus of
the epileptic changes (Figures 3(a) and 3(b) black circle).
A signiﬁcant but weak correlation is observed between the
individual T/N ratio of FDG and MET in the grade IV
gliomas (r = 0.57, P = 0.03) (Figure 3(c)). Between FLT and
MET, the T/N ratio of the MET tended to be high without
correlating with increased T/N ratio of the FLT because
the oligodendroglioma components were included in the
g r a d eI Io rg r a d eI I Ig l i o m a s( F i g u r e s3(d) and 3(e)). We
observed the same ﬁndings on the correlation between FDG
and MET. On the other hand, no signiﬁcant correlation is
observed between the individual T/N ratio of FLT and MET
in the grade IV gliomas (r = 0.13, P = 0.61) (Figure 3(f)).
However, this relationship between FLT and MET is divided
into three parts. Linear regression analysis showed a signiﬁ-
cantcorrelationbetweenFLTandMET(r = 0.21,P = 0.008)
in most areas and these areas appeared as astrocytic tumors
(Figure 3(f), red circle). The T/N ratio of the MET tended to
be high without correlating with increased T/N ratio of the
FLT (r = 0.53, P = 0.014), because the oligodendroglioma
components were included in the grade IV gliomas
(Figure 3(f), blue circle). The T/N ratio of the MET tended
to be low without correlating with increased T/N ratio of the
FLT (r = 0.12, P = 0.11) because the necrotic components
were included in the grade IV gliomas (Figure 3(f),g r e e n
circle). A signiﬁcant correlation is observed between the
individualT/NratioofFDGandFLTinthegradeIVgliomas
(r = 0.54, P = 0.05). Between FDG and FLT, T/N ratio of the
FDGtendedtobehighwithcorrelatingwithlowT/Nratioof
the FLT showing a tendency toward the focus of the epileptic
changes(Figures3(g)and3(h)blackcircle).TheT/Nratioof
the FDG tended to be low without correlating with increased
T/N ratio of the FLT, because the necrotic components were
included in the grade IV gliomas (Figure 3(i), green circle).
3.5. Representative Cases. Figures 4 and 5, respectively, show
representative cases of FDG, MET, and FLT-PET studies in
anaplastic astrocytoma and glioblastoma.
3.5.1. Case 26: 31-Year-Old Female. She had an onset of con-
vulsion. FLAIR showed a high-intensity lesion (Figure 4(a)),
and Gd-enhanced MRI showed slightly enhanced lesion in
the right frontal lobe (Figure 4(b)). FDG-PET demonstrated
increased FDG uptake within the tumor (Figure 4(c)).
MET-PET demonstrated increased MET uptake within the
tumor (Figure 4(d)). FLT-PET demonstrated increased FLT
uptake within the tumor (Figure 4(e)). Areas of diﬀerent
enhancement and uptake between FDG, MET and FLT are
projectedonthetumor,inordertoperformhistologicalsam-
pling for further correlation during the resection (Figure 46 Journal of Biomedicine and Biotechnology
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Figure 2: The correlations between SUV max (FDG (a), MET (b), and FLT (c)) and Ki-67 index were determined. Analysis indicates a
more signiﬁcant correlation between the Ki-67 index and FLT SUV max (r = 0.72, P<0.001) than between the index and FDG SUV max
(r = 0.16, P = 0.24) or MET SUV max (r = 0.32, P = 0.02). The correlations between T/N ratio (FDG (d), MET (e) and FLT (f)) and Ki-67
index were determined. Analysis indicates a more signiﬁcant correlation between the Ki-67 index and FLT T/N ratio (r = 0.63, P<0.001)
than between the index and FDG T/N ratio (r = 0.33, P = 0.02) or MET T/N ratio (r = 0.39, P<0.01).
yellow arrow, red arrow). Yellow arrow demonstrates
anaplastic astrocytoma (Figure 4(f)) within T/Nr a t i oo f
FDG-PET (2.85), MET-PET (4.57) and FLT-PET (9.65). Ki-
67 index from the specimen indicated by yellow arrow was
20% (Figure 4(g)). Red arrow demonstrates diﬀuse astrocy-
toma area (Figure 4(h)) within T/N ratio of FDG-PET
(0.76), MET-PET (2.08) and FLT-PET (4.65). Ki-67 index
from the specimen indicated by red arrow was 8% (Figure
4(i)). She has been treated for anaplastic astrocytoma.
3.5.2.Case 28:51-Year-OldMale. Heexperiencedanonsetof
aphasia and Gerstmann’s syndrome and developed glioblas-
toma which was recognized with a ring-like contrast in the
lefttemporo-occipitallobeontheGd-enhancedMRI(Figure
5(a)). The MRI study did not show a uniformed contrast,
and some areas had high-intensity signal while others did
not. Similar to the MRI study results, the accumulation was
not uniform in MET-PET and FLT-PET studies. This rela-
tionship between MET and FLT is divided into three parts,
similar to the observation described in Figure 3(f). In the
blue arrow area, the contrast by MRI was not strong, but the
T/N ratio of MET was 4.31 and theT/N ratio of FLT was 3.24
with a signiﬁcant accumulation of MET. In the green arrow
area, the contrast by MRI was strong, the T/Nr a t i oo fM E T
was 1.60, and the T/N ratio of FLT was 5.72 with a signiﬁcant
accumulation of FLT. In the red arrow area, the contrast by
MRI was recognized, but the T/N ratios of MET and FLT
were both high (3.27 and 5.28; resp., Figures 5(b) and 5(c)).
He underwent craniotomy for histopathological diagnosis.
The diagnosis revealed the blue arrow area mostly with
a histological picture of oligodendroglioma (Figure 5(d))
with a Ki-67 index of 30% (Figure 5(e)) and the green
arrow area mainly with a histological picture of necrotic
tissues (Figure 5(f)) with a Ki-67 index of less than 10%
(Figure 5(g)). As for the red arrow area displaying high
accumulation of both MET and FLT, this area showed a
strong nuclear atypia with megakaryocytes with a high Ki-
67 index of 70% (Figures 5(h) and 5(i)). Taken together,
increased accumulation of both tracers (MET and FLT)
appears to indicate high-grade malignancy.
4. Discussion
Accurate tissue diagnosis of glioma is important in order
to determine appropriate therapeutic strategy and predict
prognosis. Final diagnosis of the grade of malignancy is
carried out by surgical histopathological diagnosis. However,
due to the diverse nature of gliomas within tumors, some
glioma cases tend to be diagnosed less stringent than actual
grade of malignancy through pathological diagnosis of a
specimen taken from the tumor. The image analysis using
PET has an advantage of spatial evaluation of diverse
malignant gliomas [8, 21, 22]. FDG has been widely used
as a PET tracer for diagnosis of malignant brain tumors.
The accumulation of FDG increases in highly malignant
tumors, and this method is highly speciﬁc as an image
analysis and useful for predicting prognosis [23]. However,
F DGu p t a k ei sh i ghi nt h en o rm a lb ra i nc o rt e xwh e r egl u c o s e
metabolism is active, and the diﬀerence between the normal
accumulation and brain tumors may not be detected. In
addition, FDG uptake is low in low-grade tumors, and
FDG has limitations for detecting the localization of small
tumors or accurately identifying tumor area [5, 24, 25].
Extraattentionisespeciallyrequiredfordiagnosisofgliomas.Journal of Biomedicine and Biotechnology 7
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Figure 3: Linear regression analysis of T/N ratio between FDG and MET (grade II (a), grade III (b), grade IV (c)), between FLT and MET
(gradeII(d),gradeIII(e),gradeIV(f))orbetween FDGand FLT(gradeII(g),gradeIII(h),gradeIV(i)).Asigniﬁcant butweak correlation
is observed between the individual T/N ratio of FDG and MET (r = 0.57, P = 0.03) (c). FDG T/N ratio tended to be high correlating with
low MET T/N ratio showing a tendency toward the focus of the epileptic changes (black circle). On the other hand, no signiﬁcant correlation
is observed between the individual T/N ratio of FLT and MET (r = 0.13, P = 0.61) (f). This relationship between FLT and MET is divided
into three parts. Linear regression analysis showed a signiﬁcant correlation between FLT and MET (r = 0.21, P = 0.008) in most areas
and these areas appeared as astrocytic tumors (red circle). The T/N ratio of the MET tended to be high without correlating with increased
T/N ratio of the FLT (r = 0.53, P = 0.014) because the oligodendroglioma components were included (blue circle). The T/N ratio of the
MET tended to be low without correlating with increased T/N ratio of the FLT (r = 0.12, P = 0.11) because the necrotic components were
included (green circle). A signiﬁcant correlation is observed between the individual T/N ratio of FDG and FLT in the grade IV gliomas
(r = 0.54, P = 0.05) (i). Between FDG and FLT, T/N ratio of the FDG tended to be high with correlating with low T/Nr a t i oo ft h eF L T
showing a tendency toward the focus of the epileptic changes (Figures 3(g) and 3(h) black circle). The T/N ratio of the FDG tended to be low
withoutcorrelatingwithincreasedT/NratiooftheFLT,becausethenecroticcomponentswereincludedinthegradeIVgliomas(Figure 3(i),
green circle).
Mixed neuronal and glial tumors and gliomas which easily
cause convulsions had decreased accumulation of FDG until
now [26, 27]. In our case, accumulation of FDG was high
in low-grade glioma which is frequently associated with
convulsions. It seems that additional attention is necessary
regarding the convulsive cases and accumulation of FDG.
Recently, MET and FLT have been used as tracers with
tumor speciﬁcity. MET is one of the essential amino acids
and a tracer for evaluating protein synthesis. FLT is a tracer
of labeled thymidine for evaluating DNA synthesis, and its
accumulation is considered to reﬂect tumor cell proliferation
activity[9,28,29].Inthepresentstudy,thereweresigniﬁcant
diﬀerences between the grade II gliomas and the grade IV
gliomas and no signiﬁcant diﬀerences between the grade
II gliomas and grade III gliomas in the MET-PET study.
However, the presence of tumor cells was conﬁrmed in
the area with increased accumulation of MET but poorly
d e p i c t e do nM R Is c a na n dn oi n c r e a s e da c c u m u l a t i o no f
tracers in the FDG-PET and FLT-PET studies, indicating its
usefulness as a testing modality to determine the presence of
tumor. On the other hand, the correlation of MET uptake
in the microvessel density and blood volume in tumor
or with expression of vascular endothelial cells, which are
amino acid transporters (LAT1) in tumor cells is suggested,
and the use of MET by itself seems diﬃcult for making
diagnosis since additional factors other than proliferation
activity are involved [8, 30]. Also, it has been reported that
the accumulation of MET is high in oligodendroglioma due
to the high cell density, and special attention is required for
its diﬀerentiation [22].8 Journal of Biomedicine and Biotechnology
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Figure 4: A 31-year-old woman with high intensity in the right frontal lobe in FLAIR MRI (a) and slightly enhanced lesion in Gd-enhanced
MRI (b). FDG-PET demonstrated increased FDG uptake within the tumor (c). MET-PET demonstrated increased MET uptake within the
tumor (d). FLT-PET demonstrated increased FLT uptake within the tumor (e). Areas of diﬀerent enhancement and uptake between FDG,
MET, and FLT are projected on the tumor, in order to perform histological sampling for further correlation during the resection (yellow
arrow, red arrow). Yellow arrow demonstrates anaplastic astrocytoma (f) within T/N ratio of FDG-PET (2.85), MET-PET (4.57), and FLT-
PET (9.65). Ki-67 index from the specimen indicated by yellow arrow was 20% (g). Red arrow demonstrates diﬀuse astrocytoma area (h)
within T/N ratio of FDG-PET (0.76), MET-PET (2.08), and FLT-PET (4.65). Ki-67 index from the specimen indicated by red arrow was 8%
(i).
In the FLT-PET study, there were signiﬁcant diﬀerences
between the grade II gliomas and the grade IV gliomas and
between the grade III gliomas and grade IV gliomas. In
addition, there was a signiﬁcant correlation between the Ki-
67 index and the FLT accumulation. There is a correlation
between the Ki-67 index and the MET accumulation, but
the correlation with FLT is more signiﬁcant. Hence, we
consideredthatFLT-PETwasamoreidealandattractivePET
tracer for glioma imaging than MET-PET. Furthermore, the
uptake of FLT in normal brain tissue was lower than that of
MET(SUVmax,0.20±0.05versus1.52±0.36).Itmeansthat
FLT-PET provides a low-background cerebral image. One of
the reasons for low uptake of FLT in normal brain tissue
is that FLT allows the direct measurement of cellular TK1
activity, which has been proportional to the proliferation
activity. Since, MET accumulation provides an indirect
measure of LAT1 expression in the vascular endothelial cells
and proliferation status as amino acid uptake, MET-PET
exhibits higher background than FLT-PET in normal brain
tissue. However, FLT-PET had some weak points. In our
series of WHO grade II glioma, uptake of FLT was lower
than that of MET (SUV max, 0.36 ± 0.23 versus 3.04 ± 1.56)
and the uptake ratios for tumor to normal brain were same
(T/Nr a t i o ,1 .99 ± 1.37 versus 2.03 ± 1.02). WHO grade IIJournal of Biomedicine and Biotechnology 9
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Figure 5: A 51-year-old man with glioblastoma. MRI clearly showed a ringed enhancement in the left temporo-occipital lobe (a). Areas
of diﬀerent enhancement and uptake between MET (b) and FLT (c) are projected on the tumor, in order to perform histological sampling
for further correlation during the resection (blue arrow, green arrow, red arrow). Sample from the blue arrow demonstrates glioblastoma
with oligodendroglioma (d) within high T/N ratio of MET-PET (4.31) and low T/N ratio of FLT-PET (3.24). Sample from the green arrow
demonstrates necrosis area (f) within low T/N ratio of MET-PET (1.60) and high T/N ratio of FLT-PET (5.72). Sample from the red arrow
demonstrates glioblastoma with multiple nuclear and large cells (h) within high T/N ratio of MET (3.27) and FLT-PET (5.28). Ki-67 index
was 30% for the blue arrow (e), less than 10% for the green arrow (g), and 70% for the red arrow (i). Taken together, increased accumulation
of both tracers (MET and FLT) appears to indicate high-grade malignancy.
gliomas had no contrast enhancement on Gd-enhanced
MRI. FLT uptake was similar to the low levels observed in no
enhanced lesions of MRI. FLT may be less useful in assessing
proliferation in noncontrast-enhancing tumors regardless of
the histopathology grading. Low-tracer access to the tumor
tissue may limit the metabolic trapping of FLT after the
phosphorylation even in proliferative tumors. The leakage
of FLT was observed in the area with radiation necrosis
and disrupted blood-brain barrier (BBB) that result in the
increased accumulation [5, 24, 27]. We will continue the
analysis of FLT with more patients as FLT can be quantiﬁed
by kinetic analysis. Speciﬁcally, the kinetic analysis of FLT-
PET may clarify whether the transport eﬀect or metabolic
trapping largely contribute to the increased accumulation
of FLT in the tumor. As shown in Figure 5, there were
diﬀerences in the accumulation of each tracer within the
same tumor due to the characteristics of each tracer, which
may reﬂect the diﬀerences in tissues by site. In other words,
we can predict that there are many oligodendroglioma
components in the area with high MET accumulation and
low FLT accumulation, and it is likely that the area is necrotic
when MET accumulation is low, but FLT accumulation is
high. When both tracer accumulations are high, the area is
h i g h l ym a l i g n a n ta sat u m o rs i t ea n dh a sh i g hp r o l i f e r a t i v e
ability. However, it is diﬃcult to make diﬀerential diagnosis,
determine the recurrence of tumor, and determine the
presence or absence of radiation necrosis using only one
type of PET studies [31, 32]. Our study indicated that the
combinational uses of FDG, MET, and FLT-PET help us
evaluate the diﬀerences in malignancy grade of the tissues
and predict the evaluation of histopathological components.
Furthermore, these analyses will be useful for preoperative
planning of excision area.
5. Conclusion
PET studies using FDG, MET and FLT were conducted on
54 glioma patients. We can predict that there are many
oligodendroglioma components in the area with high MET
accumulation and low FLT accumulation, and it is likely10 Journal of Biomedicine and Biotechnology
that the area is necrotic when MET accumulation is low
but FLT accumulation is high. When both MET and FLT
tracer accumulations are high, the area is highly malignant
as a tumor site and has high proliferative ability. PET
study is a noninvasive examination method, and the use
of these tracers in addition to widely used FDG-PET is
highly useful for accurate preoperative diagnosis of tumors
and identiﬁcation of tumor area for removal. We will
continue these tracer analyses to elucidate the correlation
with pathological diagnosis and radiological diagnosis.
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